1302 results about "Blood specimen" patented technology

The invention relates to the technical field of drug concentration detection, and relates to a clinical pharmaceutical blood concentration detection method, which comprises the following steps: capturing drug molecules in a blood sample based on a micro-fluidic chip, enabling a sensor to detect the drug molecules and combine with the surface of the drug molecules, and collecting high-sensitivity blood reaction data. According to the method, main variables in data are identified and utilized by adopting a principal component analysis method, so that the complexity of spectral data is effectively reduced, meanwhile, the most critical information for calculating the drug concentration is reserved, the data processing flow is optimized, the analysis speed and efficiency are improved, and the prediction of the drug concentration is more accurate; according to the method, more reliable data support is provided for clinic, the data is smoothed through the moving average algorithm, random fluctuation caused by sampling errors or external variables is reduced, the overall quality and credibility of the data are improved, errors can be obviously reduced, and therefore doctors are supported to conduct more accurate medicine dosage adjustment and curative effect evaluation.

The detection method comprises the following steps: adding an oxygen-containing solution into a blood sample, adding the oxygen-containing solution into a micro-fluidic chip, irradiating the blood sample through light sources with different wavelengths, and detecting data of absorbed light to obtain concentration information and establish a model; the contribution of hemoglobin in the measurement concentration of the blood sample is obtained by analyzing the data of the absorbed light, and finally, the blood sample is detected through the model, and the hemoglobin concentration is obtained and output. Compared with the prior art, under the condition that a blood sample is not pretreated, the hemoglobin concentration can be accurately detected, and a result is obtained; the method comprises the following steps: adding an oxygen-containing solution into a blood sample; compared with the prior art, by changing the light absorption property of hemoglobin in the blood sample, the hemoglobin can be detected more easily, and the detection accuracy is improved.

The invention discloses a blood, urine and body fluid collecting, detecting, analyzing and uploading system based on multi-sensor integration, which comprises the following modules: a blood collecting module for collecting a blood sample; the urine collection module is used for detecting urine; the body fluid collecting module is used for detecting body fluid; the data processing module is used for preprocessing data; the feature extraction and classification module is used for constructing a multi-modal feature matrix based on a neural structure search network, a support vector machine and a random forest algorithm; the anomaly detection module is used for generating a weighted anomaly score in combination with an isolated forest and a depth anomaly detection model; the time sequence analysis module is used for analyzing the health trend by using a variational auto-encoder-generative adversarial network; the health portrait and risk assessment module is used for constructing a health map by adopting a graph convolutional network; and the encryption and uploading management module is used for encrypting by using AES and RSA and managing the data access authority based on the intelligent contract. According to the invention, a multi-modal sensor and an intelligent algorithm are integrated, and collection, detection, analysis, encryption and uploading of blood, urine and body fluid are realized.

The utility model discloses a sample collection and detection device. The sample collection and detection device comprises a shell, a sampling head and a detection assembly, the sampling head is installed on the shell, the sampling head is provided with a capillary channel, and the capillary channel has a preset volume and is used for quantitatively collecting a sample. The detection assembly is arranged in the shell, and the detection assembly is matched with the sampling head and is used for receiving the sample and detecting the sample. According to the sample collection and detection device, the operation steps can be simplified, the risk that the blood sample is polluted can be reduced, the sample can be quantitatively collected, and therefore the accuracy of the detection result can be improved.

The invention provides an individualized management system and method for colorectal cancer risk prediction, and relates to the technical field of medical diagnosis and individualized medical treatment. The system comprises a multi-omics data processing module used for collecting a blood sample of a subject, extracting circulating free DNA, and sequencing cfDNA by adopting a simplified methylation sequencing technology to obtain final original data of DNA methylation characteristics; the risk prediction module is used for carrying out bioinformatics analysis on the original data of the final DNA methylation features by adopting a machine learning algorithm, extracting a methylation feature set, a tail end motif feature set and a breakpoint motif feature set, and carrying out risk prediction on the basis of the extracted feature sets; and predicting the colorectal cancer disease risk of the subject by using a pre-trained prediction model to obtain a prediction result. The problem that the risk prediction accuracy of the colorectal cancer is low is solved.

The invention relates to the field of biological devices, in particular to a blood culture bottle positive sample transfer device which comprises a connecting pipe and at least two puncture needles, the puncture needles are communicated with an opening of the connecting pipe, a protective cover is arranged on the outer wall of the connecting pipe, and the protective cover is arranged on the outer wall of the connecting pipe. And the puncture needle close to the protective cover is arranged in the protective cover. A connecting seat is arranged at one end of the connecting tube, the protective cover is arranged on the outer wall of the connecting seat, and the puncture needle is communicated with the connecting tube through the connecting seat. And the protective cover is in threaded connection with the connecting seat. The device has the advantages that the blood sample in the culture bottle can be conveniently transferred, and pollution and biological hazards to the blood sample are avoided as much as possible.

The invention relates to the technical field of blood centrifugation, and particularly discloses a centrifugal device for blood analysis, which comprises a centrifugal machine body and a centrifugal tube, and also comprises: a pick-and-place assembly, which is arranged in the centrifugal machine body and is used for clamping and placing the centrifugal tube; the auxiliary assembly is arranged on the taking and placing assembly, and the auxiliary assembly is used for keeping the centrifugal tube stable and inclined in the centrifugal process. By means of the taking and placing assembly, a plurality of centrifugal tubes containing blood samples can be conveniently clamped and placed into the centrifugal machine body, after centrifugation is completed, the multiple centrifugal tubes can be conveniently taken out of the centrifugal machine body, the multiple centrifugal tubes do not need to be taken and placed one by one, and therefore operation and use of a user can be facilitated; the centrifugal tube can be kept stable in the centrifugal process, the centrifugal tube is prevented from shaking in the sleeve, the blood centrifugal effect is prevented from being affected, the centrifugal tube can be in an inclined state after being placed in the sleeve, and the blood centrifugal effect is improved.

The invention discloses a sugar chain marker combination for predicting prognosis of liver cancer transarterial chemoembolization and application of the sugar chain marker combination. The invention discovers and verifies that the combination composed of NA3Fb, NA4Fb and NA4F2b can be used as a novel marker for evaluating TACE treatment reaction and prognosis by analyzing a serum sugar chain map of a liver cancer patient for the first time. Based on the marker combination, a TACE-GT prognosis scoring model and system are established, and the progression risk of a patient within 12 months after a TACE operation can be effectively distinguished by noninvasively detecting the expression levels of three carbohydrate chains in serum of the patient and calculating a specific score. The detection method provided by the invention is based on a blood sample, and has the advantages of noninvasiveness and convenience, and a risk assessment system can provide individualized curative effect prediction and decision support for clinicians before and after TACE treatment, and has important values for realizing precise treatment of liver cancer and improving prognosis of patients.

The invention provides a blood sample automatic analysis system based on artificial intelligence. The blood sample automatic analysis system based on artificial intelligence comprises a sample collection module used for automatically collecting a blood sample of a patient, a data acquisition module comprising a sensor and an imaging device and used for acquiring an image of the blood sample or original data in other forms, and a data preprocessing module, and the noise filtering module is used for carrying out noise filtering, standardization and normalization processing on the original data. According to the blood sample automatic analysis system based on artificial intelligence, by introducing a dynamic adjustment mechanism and a self-adaptive learning algorithm, the system can adjust model parameters in real time, and especially under the condition that data is insufficient or a data set has deviation, the recognition accuracy of rare diseases is greatly improved. The dynamic model training method not only improves the generalization ability of the model, but also effectively relieves the limitation of relying on a large-scale annotation data set.

The invention provides a quantitative sampling device for pathology department inspection, and relates to the technical field of sampling devices.The quantitative sampling device comprises a base, a placement rack is rotatably mounted at the top of the base through a bearing, test tubes are inserted into the surface of the placement rack at equal intervals, a mounting column is arranged at the top of one side of the placement rack, and a shaft rod is fixed to the bottom of the mounting column; compared with the prior art, each sampling assembly corresponds to one test tube, an outer barrel and an insertion tube on each sampling assembly are used for extracting and storing blood samples, and the sampling assemblies are arranged on the outer surface of the mounting column at equal intervals. The device is installed on the center column, the position of the piston rod is adjusted to different heights in advance, adjustment is conducted according to blood needing to be extracted, under the cooperation of the driving assembly and the lifting assembly, the required blood sample content is extracted from each outer barrel, collection of different items is conducted at the same time, and the sampling and collecting efficiency is improved.

The invention provides a blood coagulation factor activity detection system and method and a storage medium, and the system comprises a quantum dot fluorescent probe array module which comprises a plurality of quantum dot fluorescent probes and is used for identifying and marking different blood coagulation factors in a blood sample; the laser module is used for emitting laser beams with various preset wavelengths to the blood sample, and the various preset wavelengths are matched with excitation wavelengths of different quantum dots; the signal capturing module is used for continuously capturing a fluorescence signal corresponding to each quantum dot fluorescence probe and transmitting the fluorescence signal to the activity detection module in real time; and the activity detection module is used for recording fluorescence change signals corresponding to different blood coagulation factors, labeling blood coagulation factor types for the fluorescence change signals, and inputting an activity prediction model to obtain activity levels of different blood coagulation factors. The multi-quantum-dot fluorescent probe can efficiently detect the activity of various blood coagulation factors, and the comprehensiveness and accuracy of blood coagulation factor activity detection are improved.

The invention relates to the technical field of cancer risk prediction, in particular to a deep learning cancer risk prediction method and system based on a methylation sequence. The method comprises the following steps: acquiring DNA methylation sequencing data and reference genome annotation data in a blood sample of a cancer patient; performing functional region classification processing on the DNA methylation sequencing data according to the reference genome annotation data to obtain promoter subregion methylation data, enhancement subregion methylation data and transcription factor binding site methylation data; performing dynamic sequence similarity calculation processing on the methylation data of the promoter region to obtain a first feature vector containing importance weight of the promoter region of the cancer-related gene; the methylation sites are classified according to the functions of the methylation sites in the transcriptional regulation pathway, so that the biological interpretation of the characteristics is improved, and the synergistic effect among different functional regions can be captured.

The invention discloses a multichannel blood sample shunt detection glucometer, and belongs to the technical field of glucometers, the multichannel blood sample shunt detection glucometer comprises a base, the top side in the base is fixedly connected with a protective cover, the bottom side in the protective cover is provided with a detection disc, and the bottom side in the detection disc is provided with a mounting groove. According to the device, a driving motor drives a detection disc, a connecting shaft and a gear to rotate, the gear drives the connecting shaft, an annular block and an arc-shaped convex block to rotate under the action of a fan-shaped fluted disc, and the arc-shaped convex block can extrude a roller, a connecting rod and a second spring in the rotating process; a plurality of rollers intermittently drive a connecting rod, a spherical hinge support and a spherical hinge support to move upwards, that is, a fixed seat continuously drives a blood sample storage transparent tube to perform shaking, vibration and static settlement treatment, so that blood and a reagent in the blood sample storage transparent tube are fully mixed and reacted; therefore, the subsequent blood glucose detection precision of the equipment on the blood in the blood sample storage transparent tube is ensured.

Provided is a method for estimating a factor causing an abnormality in coagulation of a blood sample. In the method, 1) a parameter Ps relating to a coagulation reaction in a sample S and a parameter Pm relating to a coagulation reaction in a sample M are calculated, 2) an estimation as to whether the sample S is coagulation-factor-inhibitor-positive is carried out on the basis of Ps, and 3) a sample S that is not estimated to be coagulation-factor-inhibitor-positive in 2) is estimated to be lupus-anticoagulant-positive or coagulation-factor-deficient on the basis of Pm or on the basis of Ps and Pm. The sample S is a test blood sample having an extended coagulation time, the sample M is a mixed sample of the sample S and a sample N, and the sample N is a normal blood sample. Ps is calculated on the basis of a measurement point or time at which a coagulation reaction curve or a coagulation speed curve of the sample S reaches a prescribed value, and Pm is calculated on the basis of a measurement point or time at which a coagulation reaction curve or a coagulation speed curve of the sample M reaches a prescribed value.

The invention belongs to the technical field of medical detection, and discloses a blood disease high-throughput detection method based on a micro-fluidic chip and SERS (Surface Enhanced Raman Scattering) detection, which comprises the following steps: introducing a blood sample into the micro-fluidic chip with a micro-fluidic channel; the method comprises the following steps: performing SERS (Surface Enhanced Raman Scattering) detection on a blood sample through a nano-structure surface preset in a micro-fluidic channel; according to the present invention, with the microfluidic chip and the SERS technology, the high-throughput detection of the blood sample is achieved, the SERS spectrum data is collected and analyzed, the disease marker in the blood is identified, and the high-throughput detection of the blood sample is achieved through the combination of the microfluidic chip and the SERS technology. A plurality of micro-channels on the micro-fluidic chip can process a plurality of samples in parallel, the detection efficiency is remarkably improved, and the strength of Raman scattering signals can be remarkably improved by utilizing the surface enhancement effect of the SERS technology, so that high-sensitivity detection of blood disease markers is realized, and the detection cost is reduced. Accurate control and efficient separation of trace samples are achieved through the micro-fluidic chip, complex pretreatment steps are not needed, and the operation process is simplified.

The invention discloses an LC-MS / MS detection method for a palbozuril monoclonal antibody drug in a blood sample, which comprises the following steps: enriching and purifying the palbozuril monoclonal antibody drug in serum and plasma by coupling an enrichment reagent I with magnetic beads, magnetically separating the enriched blood sample, discarding the supernatant, adding a buffer solution I for leaching, and adding a buffer solution II for diluting after leaching; the method comprises the following steps: carrying out high-temperature denaturation on a diluted blood sample, sequentially adding an internal standard and protease for enzymolysis, and then adopting a high performance liquid chromatography-tandem mass spectrometry to realize high-sensitivity rapid detection of the drug concentration of the palbozuril monoclonal antibody in the blood sample. In the pretreatment process, the steps of protein reduction and alkylation are removed, the proteolysis time is shortened, the whole process is simple, convenient and rapid, and multiple requirements of clinical detection on timeliness, accuracy and low detection cost can be met at the same time.

The invention provides a dilution buffer solution for chemiluminescence detection of a blood sample. The dilution buffer solution contains 0.05 to 1 weight percent of plasmin and 0.005 to 0.02 weight percent of a de-foaming agent. The dilution buffer solution provided by the invention can reduce the jump value phenomenon in chemiluminescence detection of a blood sample, especially a repeatedly frozen and thawed blood sample, so that a correct and reliable detection result is provided for clinic, and the clinical detection time can be saved.

The invention belongs to the technical field of biology, and relates to a plasma marker for colorectal cancer diagnosis or prediction and application of the plasma marker. The invention creatively provides the application of specific enhancer RNA (eRNA58712) in serum in early diagnosis or detection of colorectal cancer, which marks that important progress is achieved in the aspect of finding novel biomarkers. The expression quantity of the eRNA58712 in serum of a colorectal cancer patient is obviously higher than that of a healthy individual, and the expression level of the eRNA58712 has an obvious positive correlation relationship with occurrence and development of the colorectal cancer, which means that rapid and accurate early recognition of the colorectal cancer can be realized on a molecular level by measuring the concentration of the eRNA58712 in a blood sample.

The application presently discloses a method of treating atherosclerosis in a human subject comprising administering an effective amount of an IL-8 inhibitor, an IL-6 inhibitor, and / or an IL-1β inhibitor, wherein the subject has a TET2 and / or DNMT3A mutation thereby treating atherosclerosis. It also discloses a method for treating atherosclerosis in a human subject comprising sequencing at least a part of a genome comprising TET2 and / or DNMT3A of one or more cells in a blood sample of the subject; determining from the sequencing whether the subject has one or more mutations in TET2 and / or DNMT3A, if it is determined that the subject has at least one TET2 and / or DNMT3A mutation, administering an IL-8 inhibitor, an IL-6 inhibitor, and / or an IL-1β inhibitor to a subject to the subject thereby treating atherosclerosis.

The invention discloses a monitoring method and system for prevention and treatment of renal fibrosis. The monitoring method comprises the following steps: collecting biomarker data in a urine sample of a patient in real time through a biosensing detector; transmitting the acquired biomarker data to a data processing center, and establishing a renal fibrosis risk assessment model of the patient; according to the risk assessment result, making a personalized prevention and treatment scheme, and monitoring the execution condition of the prevention and treatment scheme in real time; periodically detecting blood sample indexes of a patient, and combining with the biomarker data to obtain a comprehensive evaluation effect of renal fibrosis prevention and treatment; and feeding back the comprehensive evaluation result to a patient and medical staff, and adjusting the personalized prevention and treatment scheme according to the comprehensive evaluation result. According to the scheme, accurate and dynamic monitoring on prevention and treatment of the renal fibrosis can be achieved, the prevention and treatment effect of the renal fibrosis can be improved, and the life quality and prognosis of a patient are improved.

The invention belongs to the technical field of gene chips, and discloses a sheep 3K liquid chip and application thereof. The method comprises the following steps: collecting blood samples of 15 different varieties of sheep, screening and identifying 3000 SNP sites, extending each SNP site for 60bp before and after a sheep reference genome, and taking a reverse complementary sequence including the SNP sites and totally 121bp as a probe sequence; synthesizing the probe sequence to obtain a liquid phase chip; and synthesizing probe sequences of other sites by adopting the same method to obtain the sheep 3K liquid phase chip. The sheep 3K liquid chip can realize sheep genetic typing through a targeted capture sequencing technology, and has important contribution significance in researches of sheep genetic diversity analysis, variety identification, genetic relationship identification, germplasm resource improvement and the like.

The invention discloses a leukocyte-rich PRP extraction method based on a leukocyte-rich PRP extraction device. The extraction device comprises a centrifugal tube body and a tube cap which are buckled with each other, the centrifugal tube body sequentially comprises a first cavity, a second cavity and a third cavity from top to bottom, the first cavity, the second cavity and the third cavity are communicated in sequence, and the tube inner diameter of the second cavity is smaller than that of the third cavity; one end of the piston is fixedly connected to the base; one end of the second cavity is embedded in the first cavity, the other end of the second cavity is embedded in the third cavity, the base covers an opening of the third cavity through threaded connection, the volume of a collected blood sample is defined as Lml, the minimum volume of the third cavity reaching the top limit position is 0.30-0.35 * L, and the volume of the second cavity is 0.2-0.3 * L; the separating device comprises a screw rod which sequentially penetrates through the base and the piston and extends to the third cavity, and a plug and a knob cap which are connected to the two ends of the screw rod; and the plug is used for blocking the second cavity.

In some embodiments, a method for classifying elements of a blood sample is provided, the method including: digitally staining an image of the blood sample using a trained machine learning model to generate a digitally stained image; extracting one or more intermediate features generated by the trained machine learning model during the digital staining of the image; providing the one or more extracted intermediate features to a trained multi-class classifier; and employing the trained multi-class classifier to classify at least one element in the blood sample based on the one or more extracted intermediate features. Many other embodiments are also provided.

Analyzers and methods of use are disclosed, including a blood analyzer comprising a light source to transmit an optical signal; a detector to generate data indicative of optical signal intensity; a transparent sample vessel between the light source and the detector; a dispensing device to pass a first portion of the blood sample comprising whole blood or lysed blood into the vessel at a first instance of time, and to pass a plasma portion of the blood sample into the vessel at a second instance of time; a controller to cause a processor to obtain first and second data generated by the detector, the first data indicative of the optical signal passing through the first portion of the blood sample and the second data indicative of the optical signal passing through the plasma, to determine a total absorbance spectrum in which the first data is adjusted by the second data.

The invention provides a method for non-invasively evaluating the zygotic property and the fetal fraction of a double-fetal pregnant fetus. Specifically, the method provided by the invention constructs a method for noninvasive evaluation of fetal zygote by detecting and calculating relative abundance of fetal specific allele and fetal specific allele fraction of cfDNA in a blood sample. By adopting the method disclosed by the invention, the zygotic property of the fetus can be efficiently and accurately determined.

A blood cell analyzer (100) and a blood cell analysis method (300). The blood cell analysis method (300) comprises: sucking a blood sample to be tested; preparing a first determination sample and obtaining first optical information; preparing a second determination sample and obtaining second optical information; generating a first leukocyte classification scatter diagram and a second leukocyte classification scatter diagram; determining a first counting result of neutrophils of the to-be-detected blood sample based on the first leukocyte classification scatter diagram and the second leukocyte classification scatter diagram; determining an actual distribution area of neutrophils from the first leukocyte classification scatter diagram; based on a reference distribution region of neutrophils of a reference leukocyte classification scatter diagram of the normal blood sample, determining a leaf-division nucleophore distribution region from the actual distribution region; determining a second counting result of the cells falling into the leaf-separating nucleogranulocyte distribution area; and based on the first counting result and the second counting result, determining a counting result of the rod-shaped nuclear granulocytes in the to-be-detected blood sample.

The invention relates to the technical field of cardiovascular disease detection, and discloses a blood ceramide and cardiovascular event correlation analysis system, a data acquisition module is used for acquiring a plurality of blood samples of different groups of patients, acquiring blood ceramide data by using a mass spectrometry detection method, and collecting clinical index data corresponding to the patients; the data processing module is used for cleaning the acquired blood ceramide data and clinical index data, removing abnormal values and missing values, and performing standardization processing on the data to obtain processed data; the feature extraction module is used for extracting target feature data associated with the cardiovascular event from the processed data; the correlation analysis module is used for inputting the target characteristic data into a blood ceramide and cardiovascular event correlation analysis model, predicting the risk of the cardiovascular event through the correlation analysis model, formulating a personalized prevention and treatment scheme and outputting a correlation analysis result; the present invention is helpful to reveal complex relationships between blood ceramides and cardiovascular events.

The invention discloses a prediction marker and a prediction method for acute upper respiratory infection susceptibility. The prediction marker and the prediction method are used for solving the problem that current acute upper respiratory infection susceptibility risk prediction is low in accuracy. The method comprises the following steps: firstly, providing a prediction marker for acute upper respiratory infection susceptibility, wherein the prediction marker is a prediction feature combination obtained by comprehensively considering human health state blood routine data and baseline blood transcriptome data and carrying out feature processing; secondly, providing a prediction method, and obtaining a to-be-detected blood sample; and performing blood analysis based on a to-be-detected blood sample, inputting the obtained blood routine sample and the gene expression sample into a susceptibility prediction model pre-trained based on a prediction marker for susceptibility risk judgment, and obtaining a susceptibility risk assessment result of acute upper respiratory infection of a human body corresponding to the to-be-detected blood sample in a future period of time, therefore, the acute upper respiratory infection susceptibility risk of the human body in a period of time in the future can be simply, quickly and accurately predicted.

The invention belongs to the technical field of biomedicine, and particularly relates to application of ceramide as a marker in prediction of hepatocellular carcinoma microvascular invasion risk. The invention finds that the preoperative plasma ceramide CER (d18: 1 / 16: 0) level can be used for predicting the MVI of HBV-HCC patients and evaluating the postoperative prognosis of the patients for the first time. The invention provides a preoperative non-invasive detection method based on plasma ceramide CER (d18: 1 / 16: 0), and trauma of traditional histopathology detection is avoided. According to the method, the occurrence risk of the MVI can be effectively reduced by simply detecting a blood sample of a patient. According to the method, the MVI risk of a patient is evaluated through a multi-factor prediction model, and a basis is provided for personalized treatment. The method is not only suitable for preoperative MVI risk assessment, but also can assist in making postoperative follow-up visit and treatment plans, and helps to reduce the postoperative recurrence rate and improve the survival rate of patients.

The invention relates to the field of blood type detection, and particularly discloses a full-automatic blood type analyzer and a control system thereof, the quality of blood type test paper is evaluated by monitoring the damage degree, the smudginess degree and the wrinkle degree of the blood type test paper, early warning is carried out, replacement of the blood type test paper is reminded, and the situation that the blood type test paper with unqualified quality is used in blood type detection is avoided; the quality of the blood sample is evaluated by monitoring the time for collecting the blood sample, and the blood type test paper is replaced to collect the blood sample again, so that the use of unqualified blood samples in blood type detection is avoided; the temperature, the humidity and the light intensity of a blood type testing environment are collected, the influence coefficient of the testing environment on a measurement result is analyzed, whether the testing environment is poor or not is judged, and early warning and prompting are carried out; the detection accuracy and reliability of the blood type analyzer are improved from multiple dimensions, so that the blood type analyzer plays a better role in the scenes of medical first aid preliminary blood type judgment, blood type screening on a blood donation site, family self-blood type detection and the like.